



1 March 2022

Medical Developments International Limited (ASX: MVP) – Trading Halt

Description

The securities of Medical Developments International Limited ('MVP') will be placed in trading halt at the request of MVP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 3 March 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos Compliance Adviser, Listings Compliance (Melbourne)



1 March 2022

By email: tradinghaltsmelbourne@asx.com.au

Melissa Kostopoulos Compliance Adviser Listings Compliance (Melbourne) Australian Securities Exchange

Dear Melissa

Medical Developments International Limited (ASX Code: MVP) - Request for Trading Halt

Pursuant to ASX listing rule 17.1, Medical Developments International Limited ACN 106 340 667 (**Company**) requests an immediate trading halt be granted by the ASX in respect of the Company's securities prior to the commencement of trading on Tuesday, 1 March 2022.

In accordance with ASX listing rule 17.1, the Company provides the following information:

- (a) the Company is seeking the trading halt pending an announcement in relation to feedback received from the FDA on MVP's USA clinical hold response;
- (b) the Company requests that the trading halt last until the earlier of the Company releasing any announcement in relation to the FDA feedback, or until the commencement of trading on Thursday, 3 March 2022;
- (c) the Company anticipates that the trading halt will cease on it making the announcement in relation to the FDA feedback;
- (d) the Company is not aware of any reason why the trading halt should not be granted; and
- (e) the Company is not aware of any further information which needs to be disclosed to the market at the time of seeking the trading halt.

If you have any queries, please contact me.

Yours faithfully

7*94*

Mark Edwards Company Secretary Medical Developments International Limited 03 9547 1888

This document is authorised for release by the directors of the Company.